Effect of epigallocatechin gallate supplementation in schizophrenia and bipolar disorder: An 8-week, randomized, double-blind, placebo-controlled study

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Strategies that focus on the reduction of oxidative stress and inflammation may have therapeutic benefit for the treatment of schizophrenia. This clinical trial sought to determine, in a double-blind study, whether epigallocatechin gallate (EGCG), a green tea extract, is a useful adjunct to maintenance antipsychotic medication. Adults with schizophrenia, schizoaffective disorder or bipolar disorder who were maintained on antipsychotic and other psychotropic medications were randomized to supplemental EGCG or placebo. Study participants completed clinical assessments and blood draws to evaluate supplemental treatment effects on psychiatric symptoms and plasma inflammatory markers. A total of 34 participants (17 EGCG, 17 placebo) were randomized and 25 participants (14 EGCG, 11 placebo) completed the study. Both treatment groups showed significant reductions in psychotic, depressive and anxiety symptoms from baseline to end of treatment. However, EGCG did not significantly affect psychiatric symptoms or inflammatory markers, as compared with placebo. Adverse effects were mild and comparable between groups. There was no signal for a therapeutic effect of the green tea extract EGCG on psychiatric symptoms in this placebo-controlled pilot study.

Original languageEnglish (US)
Pages (from-to)21-27
Number of pages7
JournalTherapeutic Advances in Psychopharmacology
Volume3
Issue number1
DOIs
StatePublished - 2013
Externally publishedYes

Fingerprint

Bipolar Disorder
Schizophrenia
Placebos
Psychiatry
Tea
Antipsychotic Agents
Therapeutics
Therapeutic Uses
Double-Blind Method
Psychotic Disorders
epigallocatechin gallate
Oxidative Stress
Anxiety
Maintenance
Clinical Trials
Depression
Inflammation

Keywords

  • anxiety
  • cytokines
  • depression
  • green tea
  • nitric oxide synthase inhibitor
  • schizophrenia

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Psychology (miscellaneous)

Cite this

@article{6a0bdcf9e9b64d61a8d4612a680da846,
title = "Effect of epigallocatechin gallate supplementation in schizophrenia and bipolar disorder: An 8-week, randomized, double-blind, placebo-controlled study",
abstract = "Strategies that focus on the reduction of oxidative stress and inflammation may have therapeutic benefit for the treatment of schizophrenia. This clinical trial sought to determine, in a double-blind study, whether epigallocatechin gallate (EGCG), a green tea extract, is a useful adjunct to maintenance antipsychotic medication. Adults with schizophrenia, schizoaffective disorder or bipolar disorder who were maintained on antipsychotic and other psychotropic medications were randomized to supplemental EGCG or placebo. Study participants completed clinical assessments and blood draws to evaluate supplemental treatment effects on psychiatric symptoms and plasma inflammatory markers. A total of 34 participants (17 EGCG, 17 placebo) were randomized and 25 participants (14 EGCG, 11 placebo) completed the study. Both treatment groups showed significant reductions in psychotic, depressive and anxiety symptoms from baseline to end of treatment. However, EGCG did not significantly affect psychiatric symptoms or inflammatory markers, as compared with placebo. Adverse effects were mild and comparable between groups. There was no signal for a therapeutic effect of the green tea extract EGCG on psychiatric symptoms in this placebo-controlled pilot study.",
keywords = "anxiety, cytokines, depression, green tea, nitric oxide synthase inhibitor, schizophrenia",
author = "Jennifer Loftis and Clare Wilhelm and Marilyn Huckans",
year = "2013",
doi = "10.1177/2045125312464103",
language = "English (US)",
volume = "3",
pages = "21--27",
journal = "Therapeutic Advances in Psychopharmacology",
issn = "2045-1253",
publisher = "Sage Publications",
number = "1",

}

TY - JOUR

T1 - Effect of epigallocatechin gallate supplementation in schizophrenia and bipolar disorder

T2 - An 8-week, randomized, double-blind, placebo-controlled study

AU - Loftis, Jennifer

AU - Wilhelm, Clare

AU - Huckans, Marilyn

PY - 2013

Y1 - 2013

N2 - Strategies that focus on the reduction of oxidative stress and inflammation may have therapeutic benefit for the treatment of schizophrenia. This clinical trial sought to determine, in a double-blind study, whether epigallocatechin gallate (EGCG), a green tea extract, is a useful adjunct to maintenance antipsychotic medication. Adults with schizophrenia, schizoaffective disorder or bipolar disorder who were maintained on antipsychotic and other psychotropic medications were randomized to supplemental EGCG or placebo. Study participants completed clinical assessments and blood draws to evaluate supplemental treatment effects on psychiatric symptoms and plasma inflammatory markers. A total of 34 participants (17 EGCG, 17 placebo) were randomized and 25 participants (14 EGCG, 11 placebo) completed the study. Both treatment groups showed significant reductions in psychotic, depressive and anxiety symptoms from baseline to end of treatment. However, EGCG did not significantly affect psychiatric symptoms or inflammatory markers, as compared with placebo. Adverse effects were mild and comparable between groups. There was no signal for a therapeutic effect of the green tea extract EGCG on psychiatric symptoms in this placebo-controlled pilot study.

AB - Strategies that focus on the reduction of oxidative stress and inflammation may have therapeutic benefit for the treatment of schizophrenia. This clinical trial sought to determine, in a double-blind study, whether epigallocatechin gallate (EGCG), a green tea extract, is a useful adjunct to maintenance antipsychotic medication. Adults with schizophrenia, schizoaffective disorder or bipolar disorder who were maintained on antipsychotic and other psychotropic medications were randomized to supplemental EGCG or placebo. Study participants completed clinical assessments and blood draws to evaluate supplemental treatment effects on psychiatric symptoms and plasma inflammatory markers. A total of 34 participants (17 EGCG, 17 placebo) were randomized and 25 participants (14 EGCG, 11 placebo) completed the study. Both treatment groups showed significant reductions in psychotic, depressive and anxiety symptoms from baseline to end of treatment. However, EGCG did not significantly affect psychiatric symptoms or inflammatory markers, as compared with placebo. Adverse effects were mild and comparable between groups. There was no signal for a therapeutic effect of the green tea extract EGCG on psychiatric symptoms in this placebo-controlled pilot study.

KW - anxiety

KW - cytokines

KW - depression

KW - green tea

KW - nitric oxide synthase inhibitor

KW - schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84998183099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84998183099&partnerID=8YFLogxK

U2 - 10.1177/2045125312464103

DO - 10.1177/2045125312464103

M3 - Article

AN - SCOPUS:84998183099

VL - 3

SP - 21

EP - 27

JO - Therapeutic Advances in Psychopharmacology

JF - Therapeutic Advances in Psychopharmacology

SN - 2045-1253

IS - 1

ER -